ECRG2 inhibits cancer cell migration, invasion and metastasis through the down-regulation of uPA/plasmin activity

Carcinogenesis

Volumn 28, Issue 11, 2007, Pages 2274-2281

  Huang, Ge ^a   Hu, Zhi ^a,c   Li, Meining ^a   Cui, Yongping ^a   Li, Yuanyuan ^a   Guo, Liping ^a   Jiang, Wei ^a,b   Lu, Shih Hsin ^a  

^a CANCER HOSPITAL   (China)

^b BURNHAM INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESOPHAGEAL CANCER RELATED GENE 2 PROTEIN; GELATINASE A; GELATINASE B; PLASMIN; PROTEINASE; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; UROKINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CANCER INHIBITION; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; CULTURE MEDIUM; DOWN REGULATION; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; FEMALE; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IN VITRO STUDY; METASTASIS INHIBITION; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION;

ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; DNA, COMPLEMENTARY; DOWN-REGULATION; HUMANS; IMMUNOPRECIPITATION; MATRIX METALLOPROTEINASES; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PLASMIN; TUMOR SUPPRESSOR PROTEINS; URINARY PLASMINOGEN ACTIVATOR;

EID: 36148961616     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgm140     Document Type: Article

References (48)

1. Rao,J. (2003) Molecular mechanisms of glioma invasiveness: The role of proteases. Nat. Rev. Cancer, 3, 489-501.
2. Werb,Z. (1997) ECM and cell surface proteolysis: Regulating cellular ecology. Cell, 91, 439-442.
3. Brinckerhoff,C.E. et al. (2002) Matrix metalloproteinases: A tail of a frog that became a prince. Nat. Rev. Mol. Cell Biol., 3 207-214.
4. Cavallo-Medved,D. et al. (2005) Caveolin-1 mediates the expression and localization of cathepsin B, pro-urokinase plasminogen activator and their cell-surface receptors in human colorectal carcinoma cells. J. Cell Sci., 118, 1493-1503.
5. Stepanova,V.V. et al. (2002) Urokinase as a multidomain protein and polyfunctional cell regulator. Biochemistry, 67, 109-118.
6. Coussens,L. et al. (2002) Matrix metalloproteinase inhibitors and cancer: Trials and tribulations. Science, 295, 2387-2392.
7. Matter,H. et al. (2004) Recent advances in the design of matrix metalloprotease inhibitors. Curr. Opin. Drug Discov. Devel., 7 513-535.
8. Naglich,J.G. et al. (2001) Inhibition of angiogenesis and metastasis in two murine models by the matrix metalloproteinase inhibitor, BMS-275291. Cancer Res., 61, 8480-8485.
9. Kazal,L. et al. (1948) Isolation of a crystalline trypsin inhibitor-anticoagulant protein from pancreas. J. Am. Chem. Soc., 70, 3034-3040.
10. Williamson,M. et al. (1984) Secondary structure in the solution conformation of the proteinase inhibitor IIA from bull seminal plasma by nuclear magnetic resonance. J. Mol. Biol., 173, 341-359.
11. Laskowski,M.Jr et al. (1987) Ovomucoid third domains from 100 avian species: Isolation, sequences, and hypervariability of enzyme-inhibitor contact residues. Biochemistry, 26, 202-221.
12. Empie,M. et al. (1982) Thermodynamics and kinetics of single residue replacements in avian ovomucoid third domains: Effect on inhibitor interactions with serine proteinase. Biochemistry, 21 2274-2284.
13. Takahashi,C. et al. (1998) Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK. Proc. Natl Acad. Sci. USA, 95, 13221-13226.
14. Oh,J. et al. (2001) The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell, 107, 789-800.
15. Liu,L.T. et al. (2003) Histone deacetylase inhibitor up-regulates RECK to inhibit MMP-2 activation and cancer cell invasion. Cancer Res., 63, 3069-3072.
16. Span,P.N. et al. (2003) Matrix metalloproteinase inhibitor reversion-inducing cysteine-rich protein with kazal motifs: A prognostic marker for good clinical outcome in human breast carcinoma. Cancer 97, 2710-2715.
17. Masui,T. et al. (2003) RECK expression in pancreatic cancer: Its correlation with lower invasiveness and better prognosis. Clin. Cancer Res., 9, 1779-1784.
18. Huhtala,M.L. et al. (1962) Purification and characterization of a tumor-associated trypsin inhibitor from the urine of a patient with ovarian cancer. J. Biol. Chem., 257, 13713-13716.
19. Paju,A. et al. (2001) The levels of trypsinogen isoenzymes in ovarian tumour cyst fluids are associated with promatrix metalloproteinase-9 but not promatrix metalloproteinase-2 activation. Br. J. Cancer, 84, 1363-1371.
20. Moilanen,M. et al. (2003) Tumor-associated trypsinogen-2 (trypsinogen-2) activates procollagenases (MMP-1, -8, -13) and stromelysin-q (MMP-3) and degrades type I collagen. Biochemistry, 42, 5414-5420.
21. Prikk,K. et al. (2001) Association of trypsin-2 with activation of gelatinase B and collagenase-2 in human bronchoalveolar lavage fluid in vivo. Ann. Med., 33, 437-444.
22. Stenman,U. (2002) Tumor-associated trypsin inhibitor. Clin. Chem., 48, 1206-1209.
23. Cui,Y.P. et al. (2003) ECRG2, a novel candidate of tumor suppressor gene in the esophageal carcinoma, interacts directly with metallothionein 2A and links to apoptosis. Biochem. Biophys. Res. Commun., 302, 904-915.
24. Yue,C.M. et al. (2004) Short tandem repeat polymorphism in a novel esophageal cancer-related gene (ECRG2) implicates susceptibility to esophageal cancer in Chinese population. Int. J. Cancer, 108 232-236.
25. Girard,L. et al. (2000) Genome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer, and loci clustering. Cancer Res., 60, 4894-4906.
26. Su,T. et al. (1998) Cloning and identification of cDNA fragments related to human esophageal cancer. Zhonghua Zhong Liu Za Zhi, 20, 254-257.
27. Lopez-Rivera,E. et al. (2005) Matrix metalloproteinase 13 mediates nitric oxide activation of endothelial cell migration. Proc. Natl Acad. Sci. USA, 102, 3685-3690.
28. Hu,Z. et al. (2005) Overexpression of osteopontin is associated with more aggressive phenotypes ia human non-small cell lung cancer. Clin. Cancer Res., 11, 4646-4652.
29. Huang, G. et al. (2005) Monoclonal antibodies to esophageal cancer-related gene 2 protein. Hybridoma, 24, 86-91.
30. Shimada,H. et al. (1981) Use of chromogenic substrate S-2251 for determination of plasminogen activator in rat ovaries. Thromb. Haemost. (Stuttgart), 46, 507-510.
31. Dano,K. et al. (2005) Plasminogen activation and cancer. Thromb. Haemost., 93, 676-681.
32. Mazaud,S. et al. (2005) Basal membrane remodeling during follicle histogenesis in the fat ovary: Contribution of proteinases of the MMP and PA families. Dev. Biol., 277, 403-416.
33. Morgan,H. et al. (2005) Human breast cancer cell-mediated bone collagen degradation requires plasminogen activation and matrix metalloproteinase activity. Cancer Cell Int., 5, 1.
34. Baramova,E.N. et al. (1997) Involvement of PA/plasmin system in the processing of pro-MMP-9 and in the second step of pro-MMP-2 activation. FEBS Lett., 405, 157-162.
35. Keski-Oja,J. et al. (1992) Proteolytic processing of the 72,000-Da type IV collagenase by urokinase plasminogen activator. Exp. Cell Res., 202, 471-476.
36. Ellis,V. et al. (1989) Plasminogen activation initiated by single-chain urokinase-type plasminogen activator. Potentiation by U937 monocytes. J. Biol. Chem., 264, 2185-2188.
37. Billottet,C. et al. (2004) Targets of fibroblast growth factor 1 (FGF-1) and FGF-2 signaling involved in the invasive and tumorigenic behavior of carcinoma cells. Mol. Biol. Cell, 15, 4725-4734.
38. Feliciani,C. et al. (2003) Urokinase plasminogen activator mRNA is induced by EL-1alpha and TNF-alpha in in vitro acantholysis. Exp. Dermatol., 12, 466-471.
39. Sieuwerts,A.M. et al. (1998) Urokinase-type-plasminogen-activator (uPA) production by human breast (myo) fibroblasts in vitro: influence of transforming growth factor-beta(1) (TGF beta(1)) compared with factor(s) released by human epithelial-carcinoma cells. Int. J. Cancer, 76, 829-835.
40. Romer,J. et al. (2004) The urokinase receptor as a potential target in cancer therapy. Curr. Pharm. Des., 10, 2359-2376.
41. Wei,Y. et al. (2005) Regulation of alpha5beta1 integrin conformation and function by urokinase receptor binding. J. Cell Biol., 168, 501-511.
42. Andreasen,P.A. et al. (1990) Plasminogen activator inhibitors: hormonally regulated serpins. Mol. Cell. Endocrinol., 68, 1-19.
43. Biliran,H. et al. (2001) Pleiotrophic inhibition of pericellular urokinase-type plasminogen activator system by endogenous tumor suppressive maspin. Cancer Res., 61, 8676-8682.
44. Alizadeh,H. et al. (1995) Tissue-type plasminogen activator-induced invasion and metastasis of murine melanomas. Curr. Eye Res., 14, 449-458.
45. Ma,D. et al. (1997) Inhibition of metastasis of intraocular melanomas by adenovirus-mediated gene transfer of plasminogen activator inhibitor type-1 in an athymic mouse model. Blood, 90, 2738-2746.
46. Liu,G. et al. (1995) Co-expression of urokinase, urokinase receptor and PAI-1 is necessary for optimum invasiveness of cultured lung cancer cells. Int. J. Cancer, 60, 501-506.
47. Bajou,K. et al. (1998) Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat. Med. 4, 923-928.
48. Monea,K. et al. (2002) Plasmin activates pro-matrix metalloproteinase-2 with a membrane-type 1 matrix metalloproteinase-dependent mechanism. J. Cell. Physiol., 192 160-170.